Impaired atrial synchronicity in patients with metabolic syndrome associated with insulin resistance and independent of hypertension

Hypertension Research

Volumn 32, Issue 9, 2009, Pages 791-796

  Li, Shao Hua ^a   Yang, Bo ^a   Gong, Hui Ping ^a   Tan, Hong Wei ^a   Zhong, Ming ^a   Zhang, Yun ^a   Zhang, Wei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; ORAL ANTIDIABETIC AGENT;

A WAVE; ADULT; ARTICLE; ATRIAL SYNCHRONICITY; CAUSAL ATTRIBUTION; CONTROLLED STUDY; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM CONDUCTION; HEART ATRIUM SEPTUM; HEART LEFT ATRIUM; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE POTENTIAL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; P WAVE; PROGNOSIS; TISSUE DOPPLER IMAGING;

AGED; ARRHYTHMIAS, CARDIAC; CHINA; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART; HEART ATRIA; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 70249099543     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.105     Document Type: Article

References (34)

1. Miller JT, O'Rourke RA, Crawford MH. Left atrial enlargement: An early sign of hypertensive heart disease. Am Heart J 1988; 116: 1048-1051.
2. Beinart R, Boyko V, Schwammenthal E, Kuperstein R, Sagie A, Hod H, Matetzky S, Behar S, Eldar M, Feinberg MS. Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol 2004; 44: 327-334.
3. Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Kober L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALIANT Echo study. Eur Heart J 2009; 30: 56-65.
4. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008; 117 1255-1260.
5. Nicolaou VN, Papadakis JE, Karatzis EN, Dermitzaki SI, Tsakiris AK, Skoufas PD. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology 2007; 58: 21-25.
6. Wang TJ, Parise H, Levy D, D'Agostino Sr RB, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-2477.
7. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-318.
8. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, Smith NL, Heckbert SR. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166: 2322-2328.
9. Van Beeumen K, Duytschaever M, Tavernier R, Van de Veire N, De Sutter J. Intra- and interatrial asynchrony in patients with heart failure. Am J Cardiol 2007; 99: 79-83.
10. Li SH, Yang B, Gong HP, Tan HW, Zhong M, Zhang Y, Zhang W. Impaired left ventricular synchronicity in patients with metabolic syndrome, regardless of hypertension. J Hypertens 2009; 27: 869-875.
11. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation: Belgium, 2005.
12. Lip GY, Watson RD. ABC of atrial fibrillation. Differential diagnosis of atrial fibrillation. BMJ 1995; 311: 1495-1498.
13. Sawhney NS, Feld GK. Diagnosis and management of typical atrial flutter. Med Clin North Am 2008; 92: 65-85.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987; 9: II53-II60.
16. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, 2nd edn. Springer: New York, 2006, pp 53-84.
17. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis. Eur Heart J 2007; 28: 457-462.
18. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pacing Clin Electrophysiol 2003; 26: 436-439.
19. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541-1545.
20. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6: 367-374.
21. Benjamin E, Levy D, Vaziri S, D'Agostino R, Belanger A, Wolf P. Independent risk factors for atrial fibrillation in a population based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844.
22. Tang RB, Dong JZ, Liu XP, Long DY, Yu RH, Kalifa J, Ma CS. Metabolic syndrome and risk of recurrence of atrial fibrillation after catheter ablation. Circ J 2009; 73: 438-443.
23. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
24. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
25. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the proinflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002; 87: 1419-1422.
26. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-3265.
27. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104 2886-2891.
28. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104: 174-180.
29. Kim YH, Lim DS, Lee JH, Shim WJ, Ro YM, Park GH, Becker KG, Cho-Chung YS, Kim MK. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 2003; 35: 336-349.
30. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the hePrt in diabetes: Part 2: potential mechanisms. Circulation 2002; 105: 1861-1870.
31. Everett IV TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4: S24-S27.
32. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, KuhnRegnier F, De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001; 38: 883-891.
33. Merckx K, De Vos C, Palmans A, Habets J, Cheriex E, Crijns H, Tieleman R. Atrial activation time determined by transthoracic Doppler tissue imaging can be used as an estimate of the total duration of atrial activation. J Am Soc Echocardiogr 2005; 18: 940-944.
34. Vesely MR, Li S, Kop WJ, Reese A, Marshall J, Shorofsky SR, Gottlieb SS, Mehra MR, Gottdiener JS. Test-retest reliability of assessment for intraventricular dyssynchrony by tissue Doppler imaging echocardiography. Am J Cardiol 2008; 101: 645-650.